依达拉奉联合血栓通治疗脑梗死的疗效及不良反应分析

目的分析脑梗死治疗中联合应用血栓通及依达拉奉的疗效及不良反应。方法88例脑梗死患者,随机分为观察组与对照组,各44例。对照组使用依达拉奉治疗,观察组在对照组基础上联合使用血栓通治疗。比较两组美国国立卫生研究院卒中量表(NIHSS)评分、治疗效果、不良反应发生情况。结果治疗后,观察组NIHSS评分为(5.03±0.79)分,低于对照组的(10.10±1.13)分,差异有统计学意义(P<0.05)。观察组治疗总有效率97.73%高于对照组的77.27%,差异有统计学意义(P<0.05)。用药期间对患者进行心电图、血常规、肝肾功能检查,均未发生异常,未出现明显的不良反应。结论对脑梗死患者应用血栓通、依达拉奉联合治疗可取得显著的疗效,且用药安全性良好,值得推广。

Efficacy and adverse reactions of edaravone combined with Xueshuantong in the treatment of cerebral infarction

Objective To analyze the efficacy and adverse reactions of edaravone combined with Xueshuantong in the treatment of cerebral infarction.Methods A total of 88 patients with cerebral infarction were randomly divided into observation group and control group,with 44 cases in each group.The control group was treated with edaravone,and the observation group was treated with Xueshuantong on the basis of the control group.The National Institutes of Health stroke scale(NIHSS)scores,therapeutic effect and occurrence of adverse reactions were compared between the two groups.Results After treatment,NIHSS score of the observation group was(5.03±0.79)points,which was lower than(10.10±1.13)points of the control group,and the difference was statistically significant(P<0.05).The total effective rate of treatment 97.73%of the observation group was higher than 77.27%of the control group,and the difference was statistically significant(P<0.05).During the medication,the patient’s electrocardiogram,blood routine,liver and kidney function tests were normal,and no obvious adverse reactions occurred.Conclusion Xueshuantong combined with edaravone has remarkable efficacy on patients with cerebral infarction,and the drug safety is good,which is worthy of promotion.